Genentech Announces Positive Results of Avastin Phase III Study in Women with Advanced Ovarian Cancer(02 Mar 2010) First Phase III Study of an Anti-Angiogenic Therapy in Advanced Ovarian Cancer to Meet Primary Endpoint Genentech, Inc. announced that a Phase III study showed the combination of Avastin® (bevacizumab) and chemotherapy followed by maintenance use of Avastin alone increased the time women with previously untreated advanced ovarian cancer lived without ...
CapitalBio Corporation Certified to Provide NimbleGen Array Services in China(16 Feb 2010) Roche NimbleGen announced that Beijing-based genomic services provider CapitalBio has officially joined the Roche NimbleGen Certified Service Provider (CSP) Program. CapitalBio has been certified to process customer samples for NimbleGen Gene ...
Herceptin now approved in the EU for patients with HER2-positive advanced stomach cancer(01 Feb 2010) First targeted biological therapy to show survival benefit in stomach cancer Roche announced that the European Commission has approved Herceptin (trastuzumab) in combination with chemotherapy for use in patients with HER2-positive metastatic stomach (gastric) cancer. The approval is based on the results from the ...
Roche establishes new medical research hub in Singapore(29 Jan 2010) Roche) announced that it will enter into a strategic alliance with Singapore’s scientific and medical institutions to set up a major new translational research hub in Singapore. This "Hub for Translational Medicine” aims to enhance the understanding ...
Galapagos and Roche initiate strategic alliance in COPD(13 Jan 2010) Research access payment of EUR 6 million for Galapagos Galapagos NV announced that it has entered into a global multi-year strategic alliance with Roche to develop potential new therapies in COPD (chronic obstructive pulmonary disease).In the alliance, Galapagos will apply its target discovery platform ...
OncoMethylome Sciences to Perform MGMT Testing in Roche Phase III Study of Avastin for Glioblastoma(07 Jan 2010) OncoMethylome's Technology is being used in Roche Clinical Trial Program with Avastin OncoMethylome Sciences announced that it has entered into an agreement with F. Hoffmann-La Roche Ltd., of Basel Switzerland, for MGMT gene promoter methylation testing in a Phase III clinical trial for the use of Avastin in newly diagnosed ...
Evolva enters discovery collaboration with Roche(05 Jan 2010) Evolva Holding SA announced that it has signed an agreement with Roche to create compounds with activity on targets in oncology and anti-infectives using Evolva’s technology platform.Roche will pay Evolva an up-front technology access fee and ...
Top